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Resumo 
A epilepsia é habitualmente definida como uma condição de predisposição crónica para convulsões. É 
de destacar que nenhum dos “fármacos antiepiléticos” utilizados na prática clinica conseguem prevenir o 
desenvolvimento de epilepsia depois de um estímulo epilético, e por isso são cada vez mais denominados de 
fármacos anticonvulsivantes em vez de antiepiléticos. Conjuntamente com o facto de que 50% dos pacientes 
tratados continuarem a experienciar convulsões, as intervenções farmacológicas nesta doença estão ainda 
longe do desejável, e consequentemente novas estratégias terapêuticas são necessárias. Apesar de controverso, 
a modulação da sinalização das neurotrofinas, em particular do BDNF tem sido vista como uma estratégia 
terapêutica promissora. 
Esta revisão tem como objetivo compilar a informação disponível relativamente ao papel da 
sinalização do BDNF na epilepsia, e os possíveis mecanismos envolvidos, tais como a modulação da 
transmissão neuronal excitatória e inibitória; “mossy fiber sprouting” e o neuropéptido Y. 
Os dados apresentados demonstram uma clara discrepância entre as observações de vários estudos. Tal 
facto pode estar relacionado com as diferenças existentes entre: 1) modelos animais; 2) o protocolo de indução 
de convulsões espontâneas recorrentes; 3) esquema terapêutico de administração do BDNF exógeno; 4) 
modulação da sinalização em modelos genéticos de BDNF. 
Conclui-se então que há necessidade de mais estudos para desvendar o papel desta neurotrofina na 
epilepsia e para aferir se a modulação das suas vias de sinalização poderá constituir estratégias terapêuticas. 
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Abstract 
Epilepsy is commonly defined as a condition of chronic predisposition for seizures. Importantly, none 
of the “antiepileptic dugs” used in clinical practice can prevent the development of epilepsy after an epileptic 
insult, and thus are increasingly referred as anti-seizure drugs rather than anti-epileptic. Together with the fact 
that about 50% of treated patients continue to experience seizures, the pharmacological intervention is far 
from the ideal, and consequently the need for new therapeutic alternatives emerges. Although controversial, 
the modulation of neurotrophin signaling, in particular of the brain-derived neurotrophic factor (BDNF), has 
been seen as promising therapeutic strategy.  
The present review aims to compile the available data related to the role of the BDNF signaling on 
epilepsy and the possible mechanisms involved such as modulation of excitatory and inhibitory neuronal 
transmission; mossy fiber sprouting, and neuropeptide Y.  
Taken together the presented data clear show a discrepancy among the available data. This could be 
related to differences in the 1) animal model; 2) induction of spontaneous recurrent seizures protocol 3) 
schedule of exogenous BDNF administration; 4) genetic models of BDNF signaling modulation.  
More studies are needed to unveil the role of this neurotrophin upon epilepsy and whether the 
modulation of its signaling pathways could be considered a therapeutic strategy. 
 
Keywords 
Neurotrophins; BDNF; TrkB; Epilepsy; A2A of Adenosine; NMDA; GABA; NPY. 
  
5 
 
 
Table of contents 
Resumo ............................................................................................................................................................................. 3 
Abstract ............................................................................................................................................................................ 4 
Table of contents .............................................................................................................................................................. 5 
List of figures .................................................................................................................................................................... 6 
List of tables ...................................................................................................................................................................... 7 
Acknowledgements .......................................................................................................................................................... 8 
Abbreviations .................................................................................................................................................................... 9 
1. Introduction ................................................................................................................................................................. 10 
2. Neurotrophins .............................................................................................................................................................. 11 
3. Epilepsies ..................................................................................................................................................................... 13 
4. Endogenous BDNF and its receptors in epilepsy and in epilepsy models ...................................................................... 16 
4.1. From seizure to an increase in BDNF levels ............................................................................................................ 18 
4.2. From increased BDNF signaling to seizures ........................................................................................................... 19 
4.2.1. BDNF influence on neuronal excitability ......................................................................................................... 20 
5. Modulation of BDNF signaling as a therapeutic strategy .............................................................................................. 25 
5.1. Is there a possible clinical application? ................................................................................................................... 29 
5.2. Is there a role for the A2A of adenosine receptors? ................................................................................................ 30 
6. Final considerations ...................................................................................................................................................... 31 
References ...................................................................................................................................................................... 32 
 
  
6 
 
List of figures 
Figure 1 –   This image illustrates MFS which occurs in the hippocampus. Neurons with cellular bodies in the GCL bifurcate 
their axons in the hilar region of dentate gyrus, and project their collaterals o CA3 and to the ML.. Cornus ammonis 3 (CA3); 
dentate gyrus (DG); dentate hylus (DH); granular cell layer; mossy fiber sprouting (MFS); molecular layer (ML). Adapted 
from (Koyama and Ikegaya, 2004) ................................................................................................ 14 
Figure 2 - Seizures lead to a fast and slow increase in BDNF. The Fast increase is dependent on: i) NMDA receptors 
activation leading directly to BDNF release; ii) conversion of pro-BDNF to mature BDNF through tPA. The slow increase of 
BDNF is dependent of an increase in intracellular calcium which further increases transcription of BDNF in a AKT/Nf-kB and 
CREB dependent manner. Tissue plasminogen activator (tPA) ..................................................... 19 
Figure 3 – BDNF may increases seizures through TrkB receptor signaling pathway. TrkB activation diminish the abundance 
of the α1 subunit of GABA and  increases the abundance of α4 subunit in GABA receptorsAdapted from (Grabenstatter et 
al., 2012) ...................................................................................................................................... 22 
  
7 
 
List of tables 
Table 1 - Studies suggesting that BDNF modulation inhibits epileptogenesis. ................................................................. 27 
Table 2 - Studies suggesting that BDNF modulation do not inhibit epileptogenesis or increases it. ................................. 28 
  
8 
 
Acknowledgements 
Se há premissa em que acredito é que nada na vida se consegue sem uma grande família e sem bons 
amigos. Estes são os grandes pilares da minha felicidade. 
 Ao longo dos últimos 3 anos tive a felicidade de estabelecer uma valiosa amizade com a principal 
responsável por todo o rigor científico, pertinência de tema e de conceitos, encadeação lógica de ideias, bem 
como de qualquer outra modesta genialidade de que esta tese de mestrado se possa valer. Apercebi-me da 
incontestável importância desta amizade recentemente, na sequência da leitura ocasional de uma frase: 
“My best friend is the one who brings out the best in me” - Henry Ford 
 Por ter sempre acreditado em mim e nas minhas competências, por toda a dedicação, celeridade na 
resolução de qualquer problema, por ter fomentado em mim o espírito da investigação desde o 2º ano de 
faculdade e, acima de tudo, pela sua boa amizade, o meu muito obrigado Professora Maria José Diógenes. É 
para mim uma grande referência, e constitui um grande orgulho ter sido orientado por si nesta tese de mestrado. 
Desejava ser poeta e ter nas minhas palavras maior arte para um agradecimento mais justo face a toda a 
amizade e todo o auxílio prestado. 
 Não posso ainda deixar de agradecer ao Doutor André Jerónimo Santos. Apesar de não ter participado 
nesta tese, foi meu mentor no meu primeiro projeto de investigação. Nunca antes tinha tido a oportunidade de 
deixar por escrito o meu agradecimento por me teres ensinado praticamente tudo o que sei de procedimentos 
de laboratório, pela infindável paciência para a minha inexperiência e para as minhas perguntas básicas. Mais 
valioso ainda para mim, muito obrigado pela tua amizade. 
 Agradeço ainda á Professora Doutora Ana Sebastião que foi o meu primeiro contacto com a ciência e 
me encaminhou para porto seguro. Tenho sempre presente que toda a investigação que fiz até agora no 
laboratório e as excelentes relações inter-humanas que aqui existem só são possíveis por uma direcção firme, 
brilhante e bondosa, e por isso estou grato por todas as oportunidades de investigação que me tem concedido. 
Agradeço ainda à Professora Sandra Vaz pela disponibilidade em ser júri desta tese, e ao Dr. Hélder Viegas, 
pelas múltiplas reuniões e e-mails trocados, por me ter ensinado medicina, e especialmente por me alimentar 
os sonhos. 
 Aos meus pais e irmã, á minha namorada, á minha família, o meu mais sincero obrigado, por serem o 
meu suporte nesta vida, por serem a base sem a qual nada do resto seria possível. Sem vocês nunca teria 
chegado ao final deste curso. São os meus grandes ídolos, obrigado por terem feito de mim o homem que sou 
hoje. 
“O homem é do tamanho do seu sonho” - Fernando Pessoa   
9 
 
Abbreviations 
A2AR: adenosine A2A receptors 
A1R: adenosine A1 receptors 
BDNF: brain derived neurotrophic factor;  
Ca2+: calcium;  
EEG: electroencephalogram;  
 GABA: gamma-aminobutyric acid; 
GFLs: glial cell line-derived neurotrophic factor family of ligands; 
K+: potassium; 
KA: kainate acid;  
MFS: mossy-fiber sprouting; 
Mg2+: magnesium 
MMP7: metalloproteinase gene matrilysin;  
MTLE: mesial temporal lobe epilepsy; 
NGF: nerve growth factor; 
NMDA: N-methyl-D-aspartate receptor;  
NPY: neuropeptide Y;  
NT: neurotrophin;  
NT-3: neurotrophin-3;  
NT-4/5: neurotrophin-4/5;  
NTF: neurotrophic factors; 
PDS: paroxysmal depolarizing shift; 
SE: status epilepticus; 
SRS: spontaneous recurrent seizures; 
TrkB-Fc: Tropomyosin receptor kinase B receptor body, scavenger for BDNF 
TrkB-FL:  Tropomyosin receptor kinase B full-length 
TrkB-Tc: Tropomyosin receptor kinase B truncated; 
 
  
10 
 
1. Introduction 
 Epilepsies are frequently devastating disorders, with a prevalence around 1% in the world’s population, 
being the third most common neurologic disorder, after dementia and stroke. There are about 40 distinct forms 
of epilepsy identified. Although 50% of this cases have a complete control of seizures and a further 25% have 
improved significantly under medication, remains 25% of patients whose disease has poor control although 
optimized therapy. Given the heterogeneous clinical presentation of the patients and the different responses to 
therapy, some authors prefer the designation epilepsies rather than epilepsy 
The definition of epilepsy and epileptic seizure have been changing since the 1981 consensus. In 2014 
a new consensus defined epileptic seizure as a transient occurrence of signs and/or symptoms due to abnormal 
excessive or synchronous neuronal activity in the brain; and epilepsy as a disorder of the brain characterized 
by an enduring predisposition to generate epileptic seizures and by the neurobiologic, cognitive, 
psychological, and social consequences of this condition, requiring the occurrence of at least one epileptic 
seizure (Fisher et al., 2014). Conversely, there are “non-epileptic” seizures, when evoked in a normal brain by 
treatments such as electroshock or chemical convulsants. The therapy for patients with seizure disorders is 
usually multimodal and it includes the treatment of underlying conditions, avoidance of precipitating factors 
and suppression of recurrent seizures with medication or surgery. However, whether any of the antiepileptic 
dugs being used in clinical practice can prevent the development of epilepsy (epileptogenesis) is uncertain, 
and so drugs are preferentially referred as anti-seizure rather than antiepileptic. Together with the evidence of 
about 20% of cases resistant to therapy, emerges the need of better therapeutic strategies. Neurotrophins, 
namely brain derived neurotrophic factor (BDNF) have been implicated in the physiopathology of epilepsy, 
and an increasing interest for a potential role in its therapeutics has been growing.  
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2. Neurotrophins 
Neurotrophic factors (NTF) are a superfamily of proteins which are known to be essential in neuronal 
survival, growth and differentiation and to have acute effects on modulation of synaptic transmission and 
plasticity. Specifically, its effects on mature neuronal circuits include modulation of synaptic efficacy and 
plasticity as Long-term potentiation (LTP) and Long-term depression (LTD); and its effects on neuronal 
circuits development include modulation of neural stem cell survival and differentiation, survival of 
differentiated neurons, axon-dendrite differentiation, growth and guidance; synapse formation and maturation 
(Huang and Reichardt, 2001).  
The NTF superfamily comprises four distinct major groups: (1) the neurotrophin (NT) family; (2) the 
glial cell line-derived neurotrophic factor family of ligands (GFLs); (3) neurotrophic cytokines (neurokines); 
and (4) the family of cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte derived 
neurotrophic factor (MANF) (Rodrigues et al. 2014).  
NT are a closely related group of secreted proteins that are initially synthesized as larger precursors 
(proneurotrophins), which undergo proteolytic cleavage to yield mature forms. In mammals, the neurotrophin 
family includes nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-
3), and neurotrophin-4/5 (NT-4/5). The biological actions of neurotrophins are mediated either by the 
activation of their cognate tropomyosin-related kinase receptor (TrkA, TrkB or TrkC), or by the activation of 
the common p75 neurotrophin receptor (p75NTR). TrkA is the high-affinity receptor for NGF (with low-
affinity binding by NT-3 in some systems) (Kaplan et al., 1991; Klein et al., 1991), TrkB is the high-affinity 
receptor for BDNF with lower-affinity binding by NT-3 and NT-4 (Berkemeier et al., 1991; Squinto et al., 
1991), and TrkC is the high-affinity receptor for NT-3 (Lamballe et al., 1991; Urfer et al., 1995).  
In addition to the high-affinity NT receptors, all of the NTs bind to the low-affinity NT receptor, 
designated as p75NTR. (Chao and Hempstead, 1995). The p75NTR is a member of the tumor necrosis factor 
(TNF) receptor superfamily, and the p75NTR activation elicit distinct cellular responses, inducing cellular 
death when binding to pro-neurotrophins namely through JNK and NADE pathways (Casaccia-Bonnefil et 
al., 1996; Friedman, 2000), and modulating the affinity and selectivity of Trk activation when binding to 
mature neurotrophin (Teng et al., 2010). Although p75NTR in the highest levels are observed perinatally, then 
it declines with age, it is also overexpressed in various pathological conditions, including epilepsies, axotomy 
and neurodegeneration (Dechant and Barde, 2002). 
In this work we review the specific role of the neurotrophin BDNF on epilepsy therefore BDNF 
signaling will be detailed in this section. 
BDNF uncleaved form, the pro-BDNF is a 32-kDa precursor, comprising 247 amino acids with N-
glycosylated and glycosulphated residues within the prodomain (Mowla et al., 2001). Following the initial 
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generation, most of the pro-BDNF is then packaged into vesicles in a regulated pathway and undergoes N-
terminal cleavage by extracellular proteases, such as plasmin, metalloproteinase gene matrilysin (MMP7) (Lu, 
2003; Pang et al., 2004), tPA/plasmin cascade and extracellular matrix-metalloproteinases (Lee et al., 2001). 
In trans-Golgi network, the ‘pro-region’ is cleaved resulting in the formation of mature BDNF (14 kDa), a 
biologically active form with C-terminal dimers (Seidah et al., 1996). This mature BDNF could be then 
released by the neurons through constitutive secretion or in an activity dependent manner (Mowla et al., 2001). 
But although BDNF is highly expressed in neurons, astrocyte and microglia are also capable of producing 
BDNF (Miklic et al., 2004). 
Pro-BDNF selectively activates its high affinity receptor, the p75NTR, mainly inducing pro-apoptotic 
signaling pathways (Teng et al., 2005) while mature BDNF binds to TrkB receptors and as well as to the 
low-affinity neurotrophin receptor p75NTR (Lahteinen et al., 2003). 
BDNF binding to the full length (FL) receptor TrkB-FL triggers autophosphorylation of the tyrosine 
residue in its intracellular domain, leading to ligand-induced dimerization in each receptor, which activates 
several intracellular signaling pathways. The major signaling pathways activated by the TrkB-FL receptors 
are; (1) PI3K/AKT/mTOR; (2) MAPK/ERK and (3) PLCγ pathways, and their downstream effectors. 
Conversely, these include PI3K stimulation of AKT, Ras stimulation of mitogen-activated protein MAPK 
cascades and PLC-γ dependent generation of inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG) 
(Segal and Greenberg, 1996; Arévalo and Wu, 2006). Which one of the pathways leads do different cellular 
responses, specifically the PI3K/AKT signalling pathway is thought to be the main responsible by chronic 
effects of BDNF in neuronal circuits, as it is the survival, growth and differentiation. Conversely, it is thought 
that this pathway can halt apoptosis through phosphorylation and inhibition of pro-apoptotic proteins such as 
Bad and caspase-9 (Zhou et al., 2000). 
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3. Epilepsies 
Epileptic seizures have been classified into partial seizures, those beginning focally in a cortical site, 
and generalized seizures, those that involve both hemispheres widely from the outset. Partial seizures account 
for around 60% of epileptic seizures and are further divided in simple, when there is preservation of 
consciousness and complex, when consciousness is impaired. Etiology of partial seizures is most commonly 
secondary to a lesion in some part of the cortex, such as a tumor, developmental malformation, damage due 
to trauma or stroke, alcohol or drug withdrawal, repeated episodes of metabolic insults, such as hypoglycemia 
(Berkovic et al., 2006; Longo, 2012). Alternatively, generalized epilepsies have usually a genetic etiology due 
to inheritance of multiple susceptibility genes, with rare exceptions as it happens with the spontaneous 
mutations in SCN1A which is responsible for catastrophic severe myoclonic epilepsy of infancy. Generalized 
epilepsies are usually categorized based on the seizure activity in absence, myoclonic and tonic-clonic seizures 
(Anon, 1981). 
What concerns to the physiopathology, a seizure results of a sudden imbalance between the excitatory 
and inhibitory forces within the network of cortical neurons in favor of a sudden-onset net excitation (Fisher 
et al., 2005). When this imbalance happens,  a group of neurons starts firing in an abnormal, excessive, and 
synchronized manner (Hammer and Hammer, 2010) which results in a wave of depolarization known as a 
paroxysmal depolarizing shift (PDS) (Somjen, 2004). 
In a normal brain, there is a protection against PDS once after an excitatory neuron fires it becomes 
more resistant to firing for a period of time. This is due in part from the effect of inhibitory neurons and the 
electrical changes within the excitatory neuron. In epilepsy the resistance of excitatory neurons to fire during 
this period is decreased (Hammer and Hammer, 2010). Conversely, the mechanisms that are generally 
responsible for the focal-onset seizures are whether a decreased inhibition or an increased excitation of 
neurons (da Silva et al., 2003; Quyen et al., 2003). 
While the mechanisms of decreased inhibition are mainly relate to defective GABAergic system, the 
mechanisms leading to increased excitation include increased activation of N-methyl-D-aspartate receptor 
(NMDA) receptors, increased synchrony between neurons due to emphatic interactions and increased 
synchrony and/or activation due to recurrent excitatory collaterals (Goldberg and Coulter, 2013). 
Importantly, neuropathological studies of patients with intractable focal-onset epilepsy have revealed 
frequent abnormalities in the limbic system, particularly in the hippocampal formation. The most common 
lesion is hippocampal sclerosis, which is CA1 and CA3 pyramidal neurons loss and end folium sclerosis (loss 
of neurons within the hilus) with relative sparing of transitional cortex measured at the mid-body of the 
anterior-posterior axis (Wieser, 2004). 
The most prominent hippocampal sclerosis is frequently found in the mesial temporal lobe epilepsy 
(MTLE) (Rudge et al., 1998) which is the most common form of partial epilepsy in young adults. More subtle 
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and apparently more common than overt hippocampal sclerosis is granule cell axon (mossy-fiber) sprouting 
(MFS) (Sutula et al., 1989). The MFS, which create monosynaptic recurrent excitation circuits, consists of 
single granule cells that bifurcate their MF axons in the hilar region, projecting the collaterals to both the 
cornus ammonis 3 (CA3) region and the molecular layer (ML). As a result some of the granule cells are 
monosynaptically interconnected (Koyama and Ikegaya, 2004), providing a substrate for positive feedback 
monosynaptic recurrent excitation (Dudek and Shao, 2004) (figure 1). 
Nonetheless, the role of MSF in epileptogenesis is controversial. The classical concept is that a 
precipitating brain insult trigger transient cascades of events that permanently enhance excitability of neuronal 
networks through mechanisms including MFS. Recent evidence suggests this permanent changes occur shortly 
after the insult, and that there is a continuous turnover of sprouted mossy fibers in epileptic patients and animal 
models. However, reversal of mossy fiber sprouting might not be antiepileptogenic, once blocking its 
development with rapamycin does not reduce seizure frequency in pilocarpine-treated mice (Buckmaster and 
Lew, 2011; Heng et al., 2013; Buckmaster, 2014). However rapamycin has side-effects (Swiech et al., 2008), 
including suppression of axon sprouting by inhibitory GABAergic interneurons and so it is not absolutely 
clear yet if MFS is just a epiphenomenon unrelated to seizure genesis as some authors recently suggest, or if 
in fact is part of epileptogenisis. 
Several animal models have been developed during the last decades and there are indeed various 
animal models with chronic brain dysfunctions thought to reflect the processes underlying human epilepsy. 
The most used models to study epilepsy include (i) the kindling model and (ii) post-status epilepticus models. 
(i) The kindling model is induced by periodic administration of brief, low-intensity electrical stimulation of 
Figure 1 –   This image illustrates MFS which occurs in the hippocampus. Neurons with cellular bodies in the GCL bifurcate their axons in the hilar region of 
dentate gyrus, and project their collaterals o CA3 and to the ML.. Cornus ammonis 3 (CA3); dentate gyrus (DG); dentate hylus (DH); granular cell layer; mossy 
fiber sprouting (MFS); molecular layer (ML). Adapted from (Koyama and Ikegaya, 2004) 
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the amygdala or other limbic structures. Initial stimulations evoke a brief electrical seizure recorded on the 
EEG without behavioral change, but repeated (e.g. 10-20) stimulations result in progressive intensification of 
seizures, culminating in tonic-clonic seizures. Once established, the enhanced sensitivity to electrical 
stimulation persists for the life of the animal. The limitation of this model is that spontaneous seizures or a 
truly epileptic condition do not occur until 100-200 stimulations have been administered. In the (ii) post-status 
epilepticus models, animals experience a prolonged epileptic crisis (status epilepticus (SE)) after injection of 
pharmacological compounds (e.g. kainate, pilocarpine; intra-cortical penicillin injection; magnesium-free 
treatment) or via electrical stimulation of (limbic) brain regions. These post-SE models are the most widely 
used models in epilepsy research today. However, not all aspects of MTLE are reproduced and the widespread 
brain damage is often a caricature of the situation in the patient. As recently reviewed, more complex 
mammalian brains and genetic model organisms including zebrafish have been less studied but offer 
substantial advantages that are becoming widely recognized (Grone and Baraban, 2015).  
These models allow exploring the three main intervention levels 1) anti-epileptogenic (prevention of 
development of transformation of the normal neuronal network into one that is chronically hyperexcitable 
(Lowenstein, 2015)), 2) anti-seizure (reduction of frequency and/or severity of seizures), and 3) disease-
modifying strategies (alteration of the natural history of the disease).  
 
ü The most used epilepsy models are kindling and post-SE (pilocarpine and kainate acid) models 
ü Three main interventions: anti-epileptogenic, anti-seizure, disease modifying 
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4. Endogenous BDNF and its receptors in epilepsy and in 
epilepsy models 
Seizures have been shown to stimulate the expression of a variety of genes, including transcription 
factors (Morgan and Curran, 1991; Kiessling and Gass, 1993), neuropeptides (Gall et al., 1991), proteases 
(Qian et al., 1993) and also neurotrophins (NT) (Gall, 1993). 
What concerns to the regulation of the levels of NTs and specifically of BDNF in the epileptic brain, 
in human, the evidence support they are increased in several cases. Accordingly, in resected hippocampal 
specimens from patients suffering from  TLE compared to control there is an increased expression of BDNF 
protein (Takahashi et al., 1999) and mRNA (Mathern et al., 1997; Murray et al., 2000). Furthermore, resected 
specimens from the hippocampus of MTLE patients show an increased NTs expression in brain areas with 
MFS. Specifically, MFS correlates with increased granular layer nerve growth factor (NGF) immunoreactivity 
and seizure frequency (Kandratavicius et al., 2013). Similarly, glioneuronal tumors correlated with medically 
chronically intractable epilepsy also express increased BDNF protein expression (Villemure, 1996). 
Recently it has been discussed the relevance of serum BDNF measurement in epileptic patients for a 
prognostic purpose. A recent study with 135 participants suggests that seizure frequency and epilepsy duration 
might be negatively correlated with serum BDNF levels independently of other factors (Hong et al., 2014). 
Regarding TrkB receptors, western-blot analysis of human epileptic neocortex samples revealed that 
they are upregulated compared with control patients (Wyneken et al., 2003). However, it is not specified in 
this study what type of receptors were evaluated, the TrkB-FL or its truncated forms. 
In Human: 
ü BDNF mRNA and protein are increased in TLE patients and glioneural tumors associated with epilepsy 
ü TrkB receptors are upregulated in human epileptic neocortex 
ü BDNF serum levels might negatively correlate with seizure frequency and epileptic duration 
 
In animal model of epilepsies induced by kainate acid (KA) administration, it was shown that BDNF 
mRNA levels gradually increase in dentate granule cells of mice from 24h of status epilepticus onwards 
reaching a maximum in 7 days (Suzuki et al., 1995; Heinrich et al., 2011). Remarkably, the same evidence 
was observed performing an electroencephalogram (EEG) analysis that shows spontaneous recurrent 
discharges progressively developing in the mouse hippocampus during the first two weeks following KA 
treatment, within the same time-frame as the BDNF increase in dentate granule cells (Heinrich et al., 2011). 
Accordingly, in the kindling model, it has also been shown an increase in BDNF mRNA expression levels 
that occur predominantly in the hippocampus bilateral granule cell layer of the dentate gyrus 1-4h after kindled 
seizure in  rat, and the maximum expression levels of BDNF mRNA occurs 2h after seizures (Lindvall et al., 
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1994; Morimoto et al., 1998; Binder et al., 2001). Moreover, adult rats treated acutely with peripheral KA 
revealed that despite robust elevation in both mRNA and protein in multiple brain regions, in the same time 
frame plasma BDNF is unchanged and cerebrospinal fluid (CSF) BDNF levels remain undetectable (Lanz et 
al., 2012). 
In KA model: 
ü BDNF mRNA and protein expression levels are increased in a way directly correlated with spontaneous recurrent 
discharges on EEG. 
ü The increased brain levels of BDNF do not correlate with changes in the CSF or plasma 
 
Interestingly, no evidences of epileptogenesis were detected in TrkB(-/-) mice even after 50 electrical 
focal stimulation of the amygdale. However, when exposed to electroshock they exhibit tonic-clonic an clonic 
seizure similar to wild-type controls. Interestingly, the available data revealed that the duration of seizure 
progressively increases with focal stimulations of the amygdala in TrkB (+/-) and TrkB (+/+) but not in TrkB 
(-/-) animals (He et al., 2004), which advances TrkB and its downstream signaling pathways as attractive 
targets for developing small molecule inhibitors for prevention of epileptogenesis.  
Interestingly in BDNF knockout mice, which lack the most important endogenous ligand for TrkB-
FL, the BDNF, there is still the promotion of epileptogenesis. This finding could be seen as a contradiction 
however, this might be explained by the activation of TrkB-FL receptors by other endogenous ligands such as 
NT-3 (He et al., 2004) and adenosine (Lee and Chao, 2001). And, indeed it was observed that BDNF knockout 
mice has an increased expression levels of NT-3 in the hippocampus which might contribute to TrkB-FL 
activation, promoting epileptogenesis progression even in the absence of BDNF (He et al., 2004). Conversely, 
in kindling model, NT-3 mRNA expression levels are usually decreased (Isackson et al., 1991; Rocamora et 
al., 1992; Kokaia et al., 1993; Suzuki et al., 1995; Mudo et al., 1996; Gall et al., 1997; Garcia et al., 1997) and 
it is also reported that the development of amygdala kindling is markedly retarded in mice heterozygous for a 
deletion of the NT-3 gene. These mice did not reach the fully kindled state (3rd grade 5 seizure) until after 28 
+/- 4 days of stimulation compared to 17 +/- 2 days in the wild-type animals (Elmer et al., 1997).  
 
In kindling: 
ü BDNF mRNA and protein are increased in hippocampus 
ü TrkB gene knockout prevents epileptogenesis in kindling model 
ü BDNF gene knockout only impairs epileptogenesis in kindling model 
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Curiously, a great upregulation of truncated (Tc) TrkB and a decrease in TrkB-FL was observed in a model 
of epileptic seizures induced by magnesium-free treatment. In this experiment although calpain inhibitors have 
prevented the decrease in TrkB-FL receptors levels, the impairment on TrkB-FL mediated signaling pathways 
was not recovered (Xie et al., 2014). This fact was explained by the increased  synthesis of TrkB-Tc which is 
known to act as a negative dominant receptor (Eide et al., 1996).  This might constitute a protection mechanism 
against the possible pro-epileptogenic effect of TrkB-FL signaling pathway activation. 
In Mg2+ free model: 
ü TrkB-FL is decreased and truncated TrkB is increased compared to control. 
ü Truncated TrkB increase is mainly due to alternative splicing of TrkB mRNA. 
ü BDNF signaling is impaired in the presence of TrkB-T1. 
 
4.1. From seizure to an increase in BDNF levels 
 
What concerns to the seizure initiating mechanism, the bursting activity in individual neurons is caused 
by a relatively long-lasting depolarization of the neuronal membrane due to influx of extracellular calcium 
(Ca2+), and generation of repetitive action potentials. With sufficient activation, there is a recruitment of 
surrounding neurons via a number of synaptic and non-synaptic mechanisms, including: (1) an increase in 
extracellular potassium (K+), which blunts hyperpolarization and depolarizes neighboring neurons; (2) 
accumulation of Ca2+ in presynaptic terminals, leading to enhanced neurotransmitter release; (3) 
depolarization-induced activation of the NMDA subtype of the excitatory amino acid receptor, which causes 
additional Ca2+ influx and neuronal activation (Lowenstein, 2015) 
The seizures being responsible for depolarization-induced activation of the synaptic NMDA subtype 
of the excitatory amino acid receptor results in an influx in Ca2+ leading to the immediate release of BDNF 
which in turn binds to and activates its high-affinity receptor, TrkB-FL (Marini et al., 2007). Moreover the 
high-frequency activity seen in seizures results in tissue plasminogen activator secretion, inducing the 
conversion of pro-BDNF to mature BDNF (Boutilier et al., 2008) (Figure 2). 
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Additionally, the influx of Ca2+ when NMDA receptor is activated leads to the activation of NF-kB 
through the AKT and ERK 1/2 pathways. NF-kB is a major survival transcriptional factor (Glazner et al., 
2000), that also plays an important role in learning and memory (Meffert et al., 2003). Activated NF-kB 
translocates to the nucleus where binds to promoter 4 of the BDNF gene increasing its transcription (Lipsky 
et al., 2001; Marini et al., 2007). The influx of Ca2+ also leads to the phosphorylation of cAMP response 
element-binding protein (CREB) in the nucleus which also binds to and activates promoter 4 of BDNF gene 
(Tao et al., 1998) (Figure 2). 
 
4.2. From increased BDNF signaling to seizures 
 
As a consequence of BDNF upregulation, there is an enhancement of fast excitatory transmission in 
pyramidal cells and dentate granule cells of adult rat hippocampus (Kang and Schuman, 1995; Levine et al., 
1995; Tanaka et al., 1997), resulting in an increase of neuronal excitability in hippocampal networks, 
promoting the occurrence of epileptiform activities (Thoenen, 1995). It has already been shown that BDNF 
potentiates synaptic transmission ex vivo (Lohof et al., 1993) and in vivo (Messaoudi et al., 1998). It has also 
been showed that ex vivo rat hippocampal slices showed hyper-excitability after acute exposure to BDNF that 
it is blocked by the inhibitor of Trk receptor phosphorylation, K252a (Scharfman, 1997). Recent evidence also 
Figure 2 - Seizures lead to a fast and slow increase in BDNF. The Fast increase is dependent on: i) NMDA receptors activation leading directly 
to BDNF release; ii) conversion of pro-BDNF to mature BDNF through tPA. The slow increase of BDNF is dependent of an increase in 
intracellular calcium which further increases transcription of BDNF in an AKT/Nf-kB and CREB dependent manner. Tissue plasminogen 
activator (tPA). 
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shows that in a rat model of massive neuronal activation upon kainate-induced seizures it was found that 
elevated neuronal expression of BDNF is associated with its detachment from the nuclear lamina, and 
translocation toward the nucleus center. In contrast, the position of stably expressed TrkB-FL remains 
unchanged after seizures (Walczak et al., 2013). Thus BDNF may interfere with gene expression after seizures. 
Also of note is that hippocampal epileptogenesis may develop as a continuous, dynamic and self-
aggravating process, in which an initial insult promotes the increase in BDNF expression, that promotes 
neuronal excitability, including MF sprouting, leading to recurrence of epileptic activities which in turn further 
increase BDNF expression in the hippocampus (Heinrich et al., 2011).  
 
4.2.1. BDNF influence on neuronal excitability  
 
As stated above, the basic mechanisms responsible for a seizure are reduction of inhibitory synaptic 
activity or enhancement of excitatory synaptic activity. Consequently, antagonists of the GABAA receptor or 
agonists of different glutamate-receptor subtypes (NMDA, AMPA, or kainic acid) trigger seizures in 
experimental animals in vivo. Additional mechanisms leading to increased excitation include increased 
synchrony between neurons due to emphatic interactions and/or activation due to recurrent excitatory 
collaterals (Goldberg and Coulter, 2013). There is increasing evidence of BDNF role in some of this 
mechanisms. 
 
Increased activation of NMDA receptors 
 
BDNF through a mechanism dependent of intraneuronal Ca2+ levels increase, facilitates glutamatergic 
synaptic transmission, mediated by increasing the efficacy of glutamate release from the presynaptic neuron 
(Drube et al., 1994; Leßmann and Heumann, 1998). Furthermore, BDNF dependent postsynaptic enhancement 
of NMDA receptor responsiveness has also been shown (Leßmann, 1998). BDNF enhances glutamate release 
(Canas et al., 2004) and increases activation (Levine et al., 1998) and phosphorylation of glutamate NMDA 
receptors (Suen et al., 1997) in the hippocampus. 
 
GABAergic transmission 
 
BDNF induce modulation of inhibitory transmission, and the most affected system is the GABAergic. 
Gamma-aminobutyric acid (GABA) type A receptor (GABAARs) mediate most fast synaptic inhibition in the 
forebrain. These receptors are constitute by different subunits, and it was observed that alteration in GABAAR 
subunit composition occur during epileptogenesis in animal models of epilepsy (Brooks-Kayal et al., 1998).  
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 (1) BDNF activates early growth response factor (Egr3) synthesis via a protein kinase C 
(PKC)/mitogen-activated protein kinase (MAPK)-dependent pathway, leading to an increase in GABAAR 
containing α-4 subunit (Roberts et al., 2006; Lund et al., 2008) (Figure 3). Interestingly,  after pilocarpine 
induced SE, GABAAR α-4 subunit mRNA expression increases as the animal develops spontaneous recurrent 
seizures (Brooks-Kayal et al., 1998, 2001).  Moreover α-4 containing GABAAR have been shown to 
desensitize rapidly (Lagrange et al., 2007). Additionally, they are very sensitive  to zinc blockade (Buhl et al., 
1996), which is physiopathology important once zinc containing mossy fibers terminals sprout from the 
granule cells and into CA3, likely depositing zinc onto newly formed α-4 containing GABAAR, causing a 
decrease response to GABA.  
(2) BDNF activates the JAK/STAT pathway through TrkB-FL receptors activation, increasing 
inducible cAMP early repressor (ICER), a member of cAMP responsive element-binding protein (CREB) 
family which lead to a decrease in GABAAR containing α-1 subunit in in vivo model (Lund et al., 2008) 
(Figure 3). . Interestingly, after pilocarpine induced SE, GABAAR α-1 mRNA expression also decreases 
(Brooks-Kayal et al., 1998, 2001). Given this evidence, one could advance that the blockade of JAK/STAT 
pathway would lead to a decrease in ICER, an increase in GABAα1R and a consequent decrease in seizures. 
However, it was shown that mutant mice lacking ICER have accelerated kindling (Kojima et al., 2008), 
developing more severe epilepsy following pilocarpine-induced SE (Porter et al., 2008). Reciprocally, ICER-
overexpressing mice show delayed kindling acquisition (Kojima et al., 2008). 
This results must be integrated with the multiple signaling pathways of JAK/STAT and ICER. As 
discussed above, ICER is responsible for increasing BDNF mRNA synthesis, which role in epileptogenesis is 
not only dependent in GABAergic neurons. Consequently, therapeutic strategy’s regarding GABA neurons 
subunits must aim more specific targets than CREB/ICER.  
Moreover, in laboratorial models BDNF was also shown to influence GABAergic neurons in other 
ways, namely inhibiting GABA release from hippocampal synaptosomes (Canas et al., 2004) and enhancing 
its uptake from synaptic and extrasynaptic sites and this way influencing neuronal excitability. This uptake 
facilitation is mediated by GAT-1 molecules at the plasma membrane of astrocytes, which time span is 
increased as a consequence of BDNF presence in cultures of neurons (Vaz et al., 2011), opposite to what 
happens in nerve endings, in which GABA uptake seems to be impaired as a consequence of BDNF (Vaz et 
al., 2008). 
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ü BDNF modulates GABAAR subunits, increasing α4 and decreasing α1 in epileptic animal models 
ü Mutant mice lacking ICER have accelerated kindling, and ICER overexpressing mice show delayed kindling 
acquisition. 
ü BDNF inhibits GABA release from hippocampal synaptosomes inhibits its uptake to synaptosomes and increases 
its uptake for astrocytes.  
 
BDNF mediates mossy fibers sprouting 
 
The involvement of BDNF in MFS can be analyzed in two different perspectives: (1) the role of BDNF 
in developing MFS and (2) the influence of BDNF on excitability once MFS is installed. 
(1) Role of BDNF in developing MFS 
Figure 3 – BDNF may increases seizures through TrkB receptor signaling pathway. TrkB 
activation diminish the abundance of the α1 subunit of GABA and  increases the abundance 
of α4 subunit in GABA receptors Adapted from (Grabenstatter et al., 2012) 
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There are complicated, apparently contradictory observations that might be attributed to different 
experimental procedures or different animal models.  
There is evidence that MFS is diminished in mice heterozygous for a deletion of the BDNF gene, in 
which BDNF expression level is substantially reduced (Vaidya et al., 1999); however, there is also a reported 
increase on MFS in the same mutant mice  (Kokaia et al., 1995b). 
There are also reports showing that infusion of BDNF into the hippocampus induces MFS (Scharfman 
et al., 2002) on contrary there are data revealing that BDNF infusion has no significant effect on MFS (Vaidya 
et al., 1999). In addition, the scavenger for BDNF, TrkB-Fc, failed to inhibit kainite-induced mossy fiber 
sprouting in hippocampal cultures (Routbort and Ryan, 1997). Moreover, transgenic mice overexpressing 
BDNF do not display significant MFS (Qiao et al., 2001). On the opposite, dispersed cultures of granule cells 
of rat hippocampus showed that MFS can be induced by locally implanted beads of BDNF and prevented with 
the coapplication of an inhibitor of TrkB phosphorylation or a functioning-blocking anti-BDNF antibody 
(Koyama et al., 2004).  
In this context a suggested interpretation is that MFS is essentially a local phenomenon that is subject 
to systemic and extrahippocampal influences and that local BDNF action in the dentate hilus trigger MFS, but 
global application of BDNF mask this effect (Koyama et al., 2004), and this may explain the inconsistency in 
the literature. 
(2) influence of BDNF on excitability upon MFS  
MF contains high levels of BDNF protein under basal conditions, and this level of BDNF undergoes further 
up-regulation after seizure onsets, in KA epilepsy model (Rudge et al., 1998).  
Electron microscopy experiments indicate that the vast majority of newly formed MF synapses 
terminates on dendritic spines of granule cells and that on average one MF forms >500 new synapses and only 
a minority (<25) contact GABAergic interneurons, being the greatest influence on excitatory neurons 
(Buckmaster et al., 2002). Given that BDNF facilitates excitatory transmission this can be a major contribution 
to excitability in epilepsy.  
On the other hand, in the healthy hippocampus, more than 90% of MF synapses terminate on 
GABAergic neurons (Acsády et al., 1998), being MF capable of releasing either glutamate or GABA to 
synaptic cleft, and peculiarly an increase in GABA expression is observed with seizure activity (Gutiérrez and 
Heinemann, 2001; Gutiérrez, 2002). However, as already discussed GABA neurons activity is decreased, 
which might be responsible for increased excitability. 
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Influence of other Neuropeptides 
 
 Although the possible deleterious effects of BDNF in the epileptic brain already detailed in this review, 
robust evidence also support it beneficial effects in some epileptic models, particularly when administered for 
long periods of time and at low dosage. One of the evidences showing a protective role of BDNF is thought 
to be mediated by the regulation of neuropeptide Y (NPY) levels.  
There are evidences that correlates the levels of  BDNF with the levels of NPY: (1) the level of NPY 
is increased in the neocortex of TLE patients and positively correlated with the BDNF level (Takahashi et al., 
1999); (2) In rat epilepsy models, BDNF up-regulation in the MF pathway is followed by an increase in NPY 
in the same brain region (Vezzani et al., 1999); (3) intrahippocampal infusion of BDNF for seven days induces 
NPY up-regulation one week after the end of the infusion (Reibel et al., 2000), a time course similar to the 
time course for the effect of BDNF on kindling model. 
There is also robust evidence of the neuroprotector effects of NPY in epilepsy models and seizure 
control. Accordingly, mice lacking the NPY gene experience spontaneous seizures and are more susceptible 
to chemically induced seizures as compared to wild-type littermates (Erickson et al., 1996). In addition, 
transgenic rats overexpressing NPY show lower seizure susceptibility (Vezzani et al., 2002). Moreover, 
epileptic rats, exhibiting unprovoked spontaneous seizures, significantly lowered seizure frequency and 
exhibited delayed progression of spontaneous seizure severity following NPY overexpression (Noe et al., 
2008).  
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5. Modulation of BDNF signaling as a therapeutic strategy  
We aimed to group the experiments by BDNF modulation schedule in anti-seizure or anti-
epileptogenesis properties (Simonato, 2014). However none of the experiments analyzed matched the anti-
seizure criteria already defined. Consequently, only the anti-epileptogenesis properties of BDNF were 
evaluated because in all experiments BDNF modulation was performed before the epileptic model develops 
SRS. 
 Epileptogenesis is the process by which the previously normal brain is functionally altered and biased 
towards the generation of the abnormal electrical activity that subserves chronic seizures (Goldberg and 
Coulter, 2013). The available data show contradictory results. Tables 1 and 2 summarize the available 
information concerning the actions of BDNF upon epileptogenesis.  
Epileptogenesis was considered whenever there were alterations in relation to control group of: 1) 
seizure stage; 2) rate of kindling development; 3) SRS either frequency or severity; 4) electrophysiological 
measurements in EEG; 5) MFS; 
 In summary there the available data show that 1) decreased levels of BDNF lead to an inhibition of 
epileptogenesis (table 1) while there are other that 2) demonstrate that increased levels of BDNF inhibits or 
increases epileptogenesis (table 2). The discrepant data collected might be due to the 1) heterogeneity of the 
animals used (rat vs mice); 2) heterogeneity of epileptic model (post-SE induced by kainate vs pilocarpine vs 
penicillin vs kindling model) and even for the same model are different protocols of induction; 3) 
heterogeneity of the modulation of BDNF levels (e.g. viral vector BDNF supplementation vs direct cannula 
administration in the brain); 4) different outcomes measured, sometimes only described as reduction of 
epileptogenesis without further description in the original article. 
 
1) Decrease in BDNF levels lead to an inhibition of epileptogenesis. This conclusion arose from studies where 
the modulation of BDNF was conducted by several ways: by the knocking down of the BDNF gene (Kokaia 
et al., 1995a; He et al., 2004; Abidin et al., 2011); by the chronic intracerebro-ventricular or by the local acute 
administration of the BDNF scavenger, the TrkB-Fc (Binder et al., 1999; Unsain et al., 2009); In all this 
conditions there was evidence supporting a reduction in epileptogenesis. 
2) Increase in BDNF levels might either inhibit or increase epileptogenesis. There are contradictory results 
depending on the used models:  i) different models of genetic overexpression of BDNF consistently show 
appearance of spontaneous seizures (Papaleo et al., 2011; Isgor et al., 2015) and/or increase of severity of 
seizures in response to an epileptic stimulus (KA) (Croll et al., 1999). This are particularly appealing results 
once seems that BDNF overexpression per si triggers SRS; ii) Viral vectors to supplement the brain with 
BDNF and FGF-2 (Paradiso et al., 2009; Bovolenta et al., 2010; Simonato and Zucchini, 2010)as well as 
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continuous administration through transplanted BDNF-secreting cells (Kuramoto et al., 2011) consistently 
inhibits epileptogenesis and reduce the frequency and severity of SRS compared to control. This apparently 
contradictory difference to genetic overexpression is an interesting object of study for which we could not 
find any consistent explanation in the literature; iii) direct administration of BDNF into the brain retrieved the 
most interesting results. Continuous intra-hippocampal infusion of BDNF have been shown to inhibit (Xu et 
al., 2004) and to potentiate (Scharfman et al., 2002) epileptogenesis. However, the same author also observed 
that multiple bolus injections in spite of continuous administration potentiates epileptogenesis (Xu et al., 
2004). It was also observed that direct BDNF infusion to hippocampal slices in electrophysiological studies 
lead to increased hyperexcitability (Scharfman, 1997). 
 A possible interpretation of this results is that genetic overexpression of BDNF is related with increased 
epileptogenesis while BDNF gene manipulation (+/-) and (-/-) is related with the inhibition of epileptogenesis. 
 The effects of BDNF supplementation in epileptic brain tissue remains relatively unclear, and 
contradictory results persist. Viral vector localized supplementation with BDNF show interesting results and 
might constitute a promising therapeutic strategy. However, better comprehension of the mechanism inherent 
to its anti-epileptogenic properties and possible side effects are needed prior to any clinical trial. 
 Also remarkable is the observation that administration of BDNF in continuous intra-hippocampal 
infusion produces distinct  results from the ones obtained by the administration in multiple bolus 
microinjections (Xu et al., 2004). Together with the observation that in BDNF (-/-) mice only modest 
impairment of epileptogenesis is observed while in TrkB (-/-) mice epileptogenesis is eliminated (He et al., 
2004), one might hypothesize that continuous administration of BDNF might downregulate the TrkB-FL 
receptors, justifying the inhibition of epileptogenesis.  
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Table 1 - Studies suggesting that BDNF modulation inhibits epileptogenesis.  
BDNF	
levels	
Strategies	to	
modulate	BDNF	
levels	
Schedule		of	
BDNF	
modulation	
Model	 Main	observations	 References	
↑	
	
	
Transplanted	 BDNF-
secreting	 cells	
genetically	
manipulated		
7	days	before	SE	 Rats,	 in	 vivo,	 i.p.	
injected	 with	 KA	 45	
mg/kg;	
Significant	amelioration	of	seizure	stage	and	reduction	of	the	number	
of	 abnormal	 spikes	 at	 7	 days	
after	KA	administration.	Enhanced	neurogenesis	
(Kuramoto	et	al.,	2011)	
Continuous	 intra-
hippocampal	
infusion	 vs	 multiple	
bolus	
microinjections	
Microinjection:	
day	 1,	 5	 and	 9;	
and;	 infusions	
14	 days	 after	
first	 electrical	
stimulation;	
Rats,	in	vivo,	kindling	
model:	 pulses	 at	 a	
frequency	 of	 60	 Hz	
and	 intensity	 500	 to	
700A;	twice	daily	for	
11	days	
Continuous	infusion	of	BDNF	caused	inhibition	of	the	development	of	
seizures	and	decreased	the	level	of	phosphorylated	TrkB	receptors;		
In	 contrast,	 multiple	 bolus	 microinjections	 of	 BDNF	 accelerated	
kindling	development	and	did	not	affect	the	level	of	phosphorylated	
TrkB	receptors	
	(Xu	et	al.,	2004)	
Viral	 vectors	 to	
locally	 supplement	
FGF-2	and	BDNF	
3	days	after	SE	 Rats,	 in	 vivo,	
pilocarpine	 (300	
mg/kg),	 interrupted	
after	 2	 hours	 with	
diazepam.	 SRS	 2-3	
weeks	after	SE	
Reduced	epileptogenesis;		
Reduced	 the	 occurrence	 of	 spontaneous	 seizures.	 Seizures	 were	
significantly	less	severe	in	vector-treated	rats	although,	on	average,	
they	had	the	same	duration	in	both	groups;	
All	 untreated	 animals	 displayed	 hippocampal	 sclerosis	 and	 SRSs.	
Animals	 treated	 had	 significant	 reduction	 of	 cell	 loss	 in	 the	
hippocampus;	
Increased	neuronogenesis	and	reduced	neuronal	damage	
(Paradiso	 et	 al.,	 2009);	
(Simonato	 and	 Zucchini,	
2010);	 (Bovolenta	 et	 al.,	
2010)	
↓	
 
BDNF	(+/-)	 n.a.	 Rats,	 in	 vivo,		
penicillin	
administered	 intra-
cortically;	
epileptiform	 activity	
at	24-29d	
Suppressed	 epileptiform	 activity;	 reduced	 levels	 of	 BDNF	 led	 to	 a	
reduction	of	absolute	Gamma	band	power	
(Abidin	et	al.,	2011)	
BDNF	(+/-)	 n.a.	 Mice,	 in	 vivo,	
kindling	 model	 (100	
Hz	 frequency,	 1s	
duration)	
Greater	than	twofold	reduction	in	the	rate	of	kindling	development;	
maintenance	of	kindling	is	unaffected	
(Kokaia	et	al.,	1995a)	
BDNF	 (-/-)	 and		
TrkB	(-/-)	
n.a.	 Mice,	 in	 vivo,	
kindling	 model	
(frequency	 of	 60	 Hz	
and	 intensity	 500	 to	
700A;	twice	daily	for	
11	 days,	 at	 age	 2-4	
months	
Modest	 impairment	of	epileptogenesis	and	 increased	hippocampal	
TrkB	 activation	 were	 detected	 in	 BDNF	 (-/-)	 mice.	 In	 contrast,	
reductions	 of	 electrophysiological	 measures	 and	 no	 behavioral	
evidence	of	epileptogenesis	were	detected	in	TrkB(-/-)	mice;	
Whereas	 TrkB	 can	 be	 activated,	 and	 epileptogenesis	 develops	 in	
BDNF(-/-)	 mice,	 the	 plasticity	 of	 epileptogenesis	 is	 eliminated	 in	
TrkB(-/-)	mice	
(He	et	al.,	2004)	
Acute,	 local,	 intra-
hippocampal	
infusion	of	TrkB-Fc	
Either	 3	 h	
before	
pilocarpine	 or	
immediately	
after	diazepam	
Rats,	 In	 vivo,	
Pilocarpine	model	45	
mg/kg;	
When	 seizures	 were	 induced	 at	 the	 time	 endogenous	 BDNF	 was	
decreased,	SE-induced	neuronal	damage	was	prevented;	Exogenous	
BDNF	infused	after	SE	increases	neuronal	damage;	
Antibodies	against	BDNF	prevent	the	early	decrease	of	TrkB	after	SE;	
Antibodies	against	BDNF	decrease	neuronal	death	after	SE	
	(Unsain	et	al.,	2009)	
Chronic,	 intra-
cerebro-ventricular	
administration	 of	
TrkB-Fc	
4	 days	 before	
first	 electrical	
stimulation	
Rats,	in	vivo,	kindling		
model	 (frequency	 of	
60	 Hz	 and	 intensity	
500	 to	 700A;	 twice	
daily	for	11	days	
Delays	kindling	development,	and	the	degree	of	penetration	of	TrkB-
Fc	 into	 the	 hippocampus	 correlates	 with	 magnitude	 of	 kindling	
inhibition	
(Binder	et	al.,	1999)	
Abbreviations: i.p.: intra-peritoneal; n.a.: not applicable 
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Table 2 - Studies suggesting that BDNF modulation do not inhibit epileptogenesis or increases it. 
BDNF	
levels	
Strategies	to	
modulate	BDNF	
levels	
Schedule		of	
BDNF	
modulation	
Model	 Main	observations	 References	
	 Transgenic	 mice	overexpressing	BDNF	 n.a.	 Mice,	 in	 vivo,	injected	 with	 KA	 45	
mg/kg;	at	8-10	weeks	
of	age	
	
Increased	seizure	severity	in	response	to	KA;	Hyperexcitability	in		CA3	
and	 entorhinal	 cortex,	 but	 not	 in	 dentate	 gyrus.	 	 CA1	 LTP	 was	
disrupted,	indicating	abnormal	plasticity;	
Models	showed	a	significant	passive	avoidance	deficit;	
(Croll	et	al.,	1999)	
 Transgenic	 mice	
overexpressing	BDNF		
n.a.	 Female	mice,	in	vivo;	
No	epileptic	stimulus	
applied	
At	age	5	–	6	months,	4	of	7		BDNF-tg		displayed	
seizures,	whereas	none	of	the	seven	WT	females	displayed	seizures;	
Impaired	 working	memory	 functions,	 reduced	 breeding	 efficiency,	
higher	 anxiety-like	 scores,	 high	 self-grooming,	 impaired	 prepulse	
inhibition	
(Papaleo	et	al.,	2011)	
↑ Transgenic	 mice	overexpressing	BDNF	 n.a.	 Mice,	 in	 vivo;	 No	epileptic	 stimulus	
applied	
Emergence	 of	 spontaneous	 seizures	 at	 6months;	 	 At	 2-3months	
moderate		MFs	
(Isgor	et	al.,	2015)	
 Direct	administration	of	 BDNF	 to	
hippocampus	 at	 a	
stable	 rhythm,	 for	 2	
weeks	
	
No	 data	
available	
Rats,	 in	 vivo;	 No	
epileptic	 stimulus	
applied	
Spontaneous	behavioral	seizures	were	observed	in	BDNF-infused	rats	
(8/32;	25%)	but	not	in	controls	(0/20;	0%);	MFS	occurred	in	5	BDNF-
treated	rats	but	no	controls;	
BDNF-infused	rats	had	increased	expression	of	NPY	in	hilar	neurons	
of	the	dentate	gyrus	relative	to	control	rats	
	
(Scharfman	et	al.,	2002)	
 Direct	administration	
of	 BDNF	 to	 dentate	
gyrus	 granule	 cell	
layer	
After	
decapitated	 at	
the	 age	 range	
30–35	days	
Rats,	 ex	 vivo,	
electrical	 current	
pulses	
Increased	 responses	 to	 orthodromic	 stimulation;	 Hyperexcitability	
evoked	 by	 repetitive	 stimulation,	 including	 multiple	 population	
spikes	and	spreading	depression.	
The	 effects	 of	 BDNF	 were	 similar	 to	 those	 produced	 by	 bath	
application	of	KA	
(Scharfman,	1997)	
Abbreviations: n.a.: not applicable 
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5.1. Is there a possible clinical application?  
 
So far it is not clear if the best therapeutic strategy for epilepsies is to down or up-regulate BDNF 
levels, or even if this might be a good approach for this disease in humans. Moreover, the clinical trials 
conducted so far aiming the BDNF modulation as a therapeutic strategy for other pathologies (amyotrophic 
lateral sclerosis and diabetic neuropathy) have shown inconclusive results (Lu et al., 2013).  
In case of up-regulating BDNF levels, there is evidence that transposition of BDNF to target injury 
regions have demonstrated to be challenging in clinical trials. However, recent experiments showed that this 
problem can be circumvented by: (1) improving BDNF delivery to target zones using different administration 
routs such as intranasal administration (Jiang et al., 2011) and (2) using BDNF mimetics (Kingwell, 2010). 
Additionally, simple alternative interventions which are known to increase BDNF in the brain should might 
have an important role, such as physical exercise (Vaynman et al., 2004; Hopkins et al., 2011; Mattson, 2012), 
intellectual stimulation (Goshen et al., 2009; Cao et al., 2011), intermittent fasting (Johnson et al., 2007; 
Harvie et al., 2011; Mattson, 2012), antidepressants (Jiang and Salton, 2013) and electroconvulsive shocks 
(Mughal et al., 2011). These simple interventions might have an important role preventing epileptogenesis in 
genetically predisposed individuals.  
Down-regulating BDNF levels, as a therapeutic strategy, has not been tried so far in clinical trials. 
Nevertheless there are observations that a human BDNF genetic polymorphism in which methionine (Met) 
substitutes for a valine (Val) amino acid impairs BDNF neural secretion (Egan et al., 2003) is associated with 
altered cognitive functions and predisposition to psychiatric illnesses such as schizophrenia, Alzheimer’s, 
depression, substance-related, and eating disorders (Egan et al., 2003; Dempster et al., 2005; Gratacòs et al., 
2007; Soliman et al., 2010; Verhagen et al., 2010). These observations empower the concept that down-
regulating BDNF with a therapeutic purpose might have serious adverse side effects. 
 
Although all the challenges related to the modulation of BDNF system, this therapeutic strategy should 
not be dismissed.  Nevertheless, it is still crucial to fully understand: (1) the differences observed in the 
different models; (2) the appropriate therapeutic schedule for BDNF signaling modulation; (3) the signaling 
pathways of BDNF responsible for decreasing seizures and epilepsy; (4) and very important, the consequences 
of modulating BDNF actions which are involved in so many different actions in the brain.  
 
 
 
 
30 
 
5.2. Is there a role for the A2A of adenosine receptors? 
 
Adenosine exerts its effects through the activation of the specific G-protein-coupled receptors: A1, 
A2A, A2B, and A3 receptors. The adenosine A1 receptors (A1R) and A2A receptors (A2AR) are the most sensitive 
to adenosine and the most abundant in the central nervous system (Fredholm et al., 2011). During a seizure, 
extracellular adenosine levels rapidly rise and are believed to play an important role in the termination of the 
seizure through binding to the inhibitory adenosine A1R (During and Spencer, 1992; Gouder et al., 2003). 
Studies have shown that the adenosine A1R agonist promotes increased latency of seizure onset, decreased 
seizure occurrence, shorter seizure duration, and reduced mortality rate in chemical-induced seizure models 
(Li et al., 2013).  
Nevertheless, adenosine levels rise significantly during epileptic seizures, which could activate all adenosine 
receptors, including the A2AR. These receptors, which are known for facilitating neuronal transmission 
(Berman et al., 2000; Pedata et al., 2001), have also reports of anticonvulsant effects in some observations 
(Huber et al., 2002). One might speculate this A2AR anticonvulsant effect might be related to interplay with 
BDNF signaling (Sebastião et al., 2011). Functionally, it has been shown that most BDNF-mediated synaptic 
actions, such as in synaptic plasticity, transmission and neurotransmitter release, are fully dependent on 
adenosine A2AR activation (Diógenes et al., 2004; Pousinha et al., 2006; Fontinha et al., 2008; Tebano et al., 
2008; Jerónimo-Santos et al., 2014; Rodrigues et al., 2014b).. 
Nevertheless, recent observation suggest that both the A2A R agonist and antagonist, CGS 21680 and 
ZM 241385, respectively, did not promote changes in seizure parameters, promoting a more determinant anti-
seizure role of A1R (Siebel et al., 2015) 
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6. Final considerations 
Down regulation of BDNF signaling, including through regulation of TrkB receptors seems to be a 
possible clinical therapeutic strategy for epilepsy. It matters, however, to have a deep comprehension of the 
consequences of continuous upregulation of BDNF in animal models before any clinical trial. Targeting 
specific brain areas known to be the epileptic focus or targeting lower mediators in the cascade, such as CREB 
might reveal a promising strategy with less adverse effects. Also, deeper assessment of the influence of BDNF 
on MFS and NMDA neurons would help to identify possible therapeutic targets, other that interfering with 
the entire BDNF signaling. 
It was also noted during this review that there are few studies of BDNF modulation after the epileptic 
model is displaying SRS, consequently it would be interesting some investigation on the anti-seizure 
properties of BDNF regarding the anti-seizure definition explored in this review. 
Also remarkably is the large heterogeneity of variables in the studies of the effects of BDNF regulation 
in epileptic models. For that purpose it would be interesting to establish a protocol with standard outcomes to 
measure anti-epileptogenic and anti-seizure properties of BDNF as well as a standard animal and epileptic 
model for this analysis capable of closely reproduce human epilepsies characteristics.   
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